Through the use of CC models, PolyIC-driven immunogenicity has been shown to be dependent on the necroptosis regulator RIPK3 in tumor cells, suggesting that RIPK3 could serve as a novel predictive marker for the personalization of cancer immunotherapy (Smola, 2016). This evidence concerns the gene RIPK3 and neoplasm.